Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

11.16 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

What's going on in today's after hours session ↗

March 31, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

March 26, 2025

Via Benzinga

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial ↗

March 19, 2025

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile.

Via Benzinga

A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts ↗

February 11, 2025

Via Benzinga

Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗

January 15, 2025

Via Benzinga

Signet Jewelers, BGM Group, StoneCo, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday ↗

March 19, 2025

Via Benzinga

Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday ↗

March 14, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts ↗

March 14, 2025

Via Benzinga

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns ↗

February 11, 2025

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.

Via Benzinga

Where Regenxbio Stands With Analysts ↗

December 11, 2024

Via Benzinga

5 Analysts Have This To Say About Regenxbio ↗

November 15, 2024

Via Benzinga

What 4 Analyst Ratings Have To Say About Regenxbio ↗

October 10, 2024

Via Benzinga

Earnings Scheduled For March 13, 2025 ↗

March 13, 2025

Via Benzinga

Assessing Regenxbio: Insights From 5 Financial Analysts ↗

September 04, 2024

Via Benzinga

Where Regenxbio Stands With Analysts ↗

August 05, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 14, 2025

Via Benzinga

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

January 14, 2025

Via Benzinga

Workday, Apollo Global To Join S&P 500 Index In Quarterly Balance ↗

December 06, 2024

They'll join the index before the open on Dec. 23 as part of a quarterly rebalance.

Via Investor's Business Daily

Topics Stocks

What's Going On With REGENXBIO Shares Monday? ↗

November 18, 2024

REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.

Via Benzinga

Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday ↗

November 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 06, 2024

Via Benzinga

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

From FN Media Group LLC

Via GlobeNewswire

7 Biotech Stocks to Buy for Their Game-Changing Potential ↗

August 08, 2024

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Via InvestorPlace

Why Is Clearside Biomedical Stock Gaining Today? ↗

June 25, 2024

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS...

Via Benzinga

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗

June 21, 2024

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.

Via Benzinga

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy ↗

June 20, 2024

The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.

Via Investor's Business Daily

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗

June 13, 2024

Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

REGENXBIO Inc. - Common Stock (NQ:RGNX)

All News about REGENXBIO Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today